Reported cash and cash equivalents of $6.3 million as of March 31, 2026. Secured a $50 million non-equity-based credit facility to fund operations through 2028. Research and development expenses increased to $5.2 million for Q1 2026 compared to $4.6 million in Q1 2025. General and administrative expenses rose to $2.3 million from $2.0 million in the prior year period. Received FDA Orphan Drug Designation for IFx-2.0 for stage IIB to stage IV cutaneous melanoma.